Showing 20 of 74 recruiting trials for “chronic-neutrophilic-leukemia”
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
👨⚕️ Kerry A Rogers, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Nov 2024View details ↗
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
👨⚕️ Uma M Borate, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06508684 ↗
Current Status of BTKi Treatment for CLL/SLL in China
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2024View details ↗
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 73 sites📅 Started May 2024View details ↗
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
👨⚕️ Jianyong Li, PhD, MD, The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2024View details ↗
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
👨⚕️ Lugui Qiu, M.D., Ph.D., Hematology Hospital of the Chinese Academy of Medical Sciences📍 6 sites📅 Started Apr 2024View details ↗
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RecruitingNCT06151730 ↗
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL
👨⚕️ Maike Buchner-Mayr, PD Dr., Technisch Universität München📍 1 site📅 Started Jan 2024View details ↗
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
RecruitingNCT06125795 ↗
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →